🧬 BioMed Pulse · 2026-11-13 02:01 UTC

BIOMED PULSE

Friday, November 13, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus disease outbreak in the Democratic Republic of the Congo has now crossed into Nigeria, making it the largest Ebola-family outbreak ever recorded in DRC, with transmission spreading across six provinces and multiple neighboring countries simultaneously. Mood: urgent — multiple concurrent outbreak fronts, but longevity science offers a counterweight with a cluster of strong Lancet Healthy Longevity findings on exercise and healthy aging.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO VIRUS DISEASE (DRC, KENYA, NIGERIA) — CRITICAL

  • As of the Nov 6 WHO Disease Outbreak News (DON625), the BVD outbreak in DRC continues sustained high-level transmission across multiple health zones, now with geographic expansion since the Oct 23 DON622 update. [1]
  • Kenya and Nigeria have both reported imported cases, extending the outbreak's footprint across three countries in the WHO African Region. [2]
  • The Sept 25 DON621 noted the outbreak had reached a new province, Sud Ubangi, in northwest DRC — indicating continued westward spread away from the initial Mongbwalu health zone in Ituri Province. [3]
  • As of July 15, WHO reported 2,124 confirmed cases and 828 deaths in DRC; case and death counts have continued to rise with every subsequent update. [4]
  • WHO has characterized this as the largest Ebola outbreak ever reported in DRC and noted it is expanding faster than any previous Ebola outbreak on record. [5]
  • The outbreak was caused by Bundibugyo virus, a distinct Ebola species from the more familiar Zaire strain; it was first detected in Mongbwalu health zone, Ituri Province. [6]
  • An imported case in Kenya (reported Oct 8) involved a patient who traveled from DRC through Uganda before being hospitalized in Kenya. [7]

SHAMONDA VIRUS — FIRST HUMAN CASE, FRANCE

  • On Oct 20, 2026, France notified WHO of the world's first documented human infection with Shamonda virus (SHAV), a rare orbivirus normally found in insects and livestock. [8]
  • The case was an immunocompromised older man from eastern France with no recent travel history; he presented with severe neurological symptoms and died. [8]
  • WHO posted the Disease Outbreak News on Nov 2, 2026, and risk assessment for the general public is currently considered low given the patient's immunocompromised status and lack of travel. [8]

YELLOW FEVER — WHO AFRICAN REGION

  • Between Jan 1 and Oct 12, 2026, nine countries in the WHO African Region reported 67 confirmed yellow fever cases including 18 deaths; affected countries include Burkina Faso, Cameroon, the Central African Republic, and others. [9]
  • Transmission activity in the Americas had also carried over into 2026 from a surge in 2025, with 79 human infections recorded across six countries in the Americas through May 26, 2026. [10]

MERS-CoV — SAUDI ARABIA

  • Between Jan 1 and Oct 5, 2026, Saudi Arabia reported eight laboratory-confirmed MERS-CoV cases including one death, detected across six locations including Riyadh, Tabuk, and Al Jouf.

PNEUMONIA OF UNDETERMINED ETIOLOGY — RUSSIA

  • On Oct 2, 2026, WHO was alerted via media reports to the death of an employee at the Irkutsk Antiplague Research Institute of Siberia and the Far East, who died from severe pneumonia of undetermined cause.
  • The case raises biosafety questions given the institutional setting; WHO posted the DON on Oct 10 and investigations are ongoing.

NIPAH VIRUS — INDIA (UPDATE)

  • In June 2026, Kerala State confirmed one laboratory-confirmed Nipah virus case in Kozhikode district: an adult male who developed neurological symptoms on May 30 and was hospitalized June 10.
  • Kozhikode has been the site of previous NiV outbreaks; the case serves as a reminder of the persistent zoonotic spillover risk in the region.

HANTAVIRUS (ANDES VIRUS) — M/V HONDIUS CRUISE SHIP

  • The Andes hantavirus outbreak linked to cruise ship M/V Hondius, first notified to WHO on May 2, 2026, was described in a fifth Disease Outbreak News update dated July 2, 2026.
  • Andes hantavirus (ANDV) is notable as the only hantavirus strain with documented person-to-person transmission, raising containment concerns beyond rodent exposure.

🧬 LONGEVITY & AGING

PHYSICAL ACTIVITY AS A LONGEVITY PILLAR — LANCET HEALTHY LONGEVITY SERIES

  • A multi-paper Lancet Healthy Longevity series frames physical activity promotion in later life as a public health priority, synthesizing evidence from research to clinical implementation, with authors including Izquierdo, Vellas, Liu-Ambrose, and de Souto Barreto.
  • One paper in the series argues for multilevel action — individual, community, and policy — to translate physical activity science into real-world healthy aging gains.
  • A scoping meta-review by King et al. in the same series maps progress and identifies remaining gaps in physical activity promotion for older adults globally.
  • A companion paper by Koemel, Valenzuela, Stamatakis, and Ahmadi reviews the relationship between sedentary behavior, movement, and healthy aging in older adults.
  • Chhetri and Chan highlight promoting physical activity for healthy aging as a particular public health priority in low- and middle-income countries.
  • Suetta argues in Lancet Healthy Longevity that physical function and muscle health, rather than chronological age alone, should be used as clinically meaningful aging clocks.

SARCOPENIA — GDF11 AND MUSCLE STEM CELL REJUVENATION

  • A study in Genes and Disease (Zhang F., 2026) found that GDF11, a circulating blood factor, restores skeletal muscle satellite cell function via the MYC transcription factor, ameliorating sarcopenia — age-related muscle loss — in preclinical models.
  • Satellite cells are the stem cells responsible for muscle repair; their declining activity is a core mechanism of sarcopenia, making GDF11-MYC signaling a potential therapeutic target.

STATIN DEPRESCRIBING IN OLDER ADULTS — FRAILTY MATTERS

  • A large population-wide retrospective cohort study using Clinical Practice Research Datalink data from England (Seeley et al., Lancet Healthy Longevity) examined statin discontinuation safety in patients 65 and older, stratifying outcomes by frailty status.
  • An accompanying editorial by Bardoczi and Rodondi asks whether frailty should guide statin deprescribing decisions in older patients, noting that benefits and risks diverge across the frailty spectrum.

ANIMAL PROTEIN, COGNITION, AND DEMENTIA SEX DISPARITY

  • A global ecological analysis published in Future Science OA (You et al., Nov 2026) found associations between national animal protein supply, cognitive aging trajectories, and female-male dementia disparities across countries.

OLDER ADULTS IN HUMANITARIAN CRISES — A LONGEVITY EQUITY ISSUE

  • A cluster of Lancet Healthy Longevity papers highlights that older adults are systematically overlooked and underserved in humanitarian emergencies, with specific gaps in malnutrition response, palliative care, and sexual and reproductive health.
  • De la Fuente-Nunez et al. and van Boetzelaer et al. propose the PARTICIPATE rights-based framework to ensure older people's health needs are addressed in humanitarian crises.

AI-BASED BIOLOGICAL AGE ESTIMATION FROM FACE PHOTOGRAPHS

  • A model development and validation study (Haugg, Lee, He, et al. including Gladyshev VN and Aerts HJ, Lancet Digital Health) introduced FAHR-Face, a foundation AI model that estimates biological age from facial photographs, with potential clinical and research applications.
  • A separate Lancet Digital Health paper found AI-based left-ventricular segmentation of cardiac MRI outperformed clinicians in mortality prediction across a retrospective multicenter study.

💊 NEW CURES & APPROVALS

ONCOLOGY SUPPLEMENTS AND UPDATES — FDA

  • RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), sponsor Janssen Biotech, received a supplemental approval; amivantamab targets EGFR and MET, relevant to non-small cell lung cancer.
  • WELIREG (belzutifan), sponsor Merck Sharp and Dohme, received a supplemental approval; belzutifan is a HIF-2-alpha inhibitor used in VHL disease-associated tumors and renal cell carcinoma.
  • ZYNLONTA (loncastuximab tesirine-lpyl), an antibody-drug conjugate from ADC Therapeutics SA, received a supplemental approval for diffuse large B-cell lymphoma.

HEMOSTASIS AND RARE DISEASE

  • HYMPAVZI (marstacimab-hncq), sponsor Pfizer Inc, received a supplemental approval; marstacimab is a tissue factor pathway inhibitor antibody indicated for hemophilia.

HORMONE THERAPY AND CARDIOVASCULAR

  • ORGOVYX (relugolix), sponsor Sumitomo Pharma America, received a supplemental approval; relugolix is an oral GnRH receptor antagonist used in advanced prostate cancer.

GENERICS AND BIOSIMILARS

  • Supplemental approvals were recorded for rosuvastatin calcium (ScieGen Pharms, ANDA206381), emtricitabine and tenofovir disoproxil fumarate (Macleods Pharms, HIV), adalimumab-atto AMJEVITA (Amgen, biosimilar), and filgrastim-ayow RELEUKO (Kashiv Biosciences).

🧪 CLINICAL TRIALS

COGNITIVE AGING INTERVENTIONS

  • Trial NCT07388043 (ClinicalTrials.gov) is evaluating AP-Brain at 1g, 3g, and 5g doses for cognitive performance in healthy middle-aged and older adults with self-reported memory problems, assessing safety and efficacy.
  • Trial NCT06269939 is investigating a theory-driven manualized memory enhancement technique specifically in healthy aging populations and those with mild cognitive impairment (MCI).
  • Trial NCT07267845 is testing whether daily supplementation with alpha-GPC (alpha-glycerophosphocholine) over 6 weeks improves cognitive function and sports performance in healthy adults.

CANCER — GLIOMA AND SOLID TUMORS

  • Trial NCT05588141 (NCI Protocol 000860) is a Phase I/II study of zotiraciclib, a CDK9 inhibitor, in patients with recurrent malignant gliomas carrying IDH1 or IDH2 mutations — a population with limited treatment options.
  • Trial NCT07672483 is evaluating IL-12 genetically engineered myeloid cells (IL-12 GEMys) in participants with relapsed or refractory solid tumors, harnessing myeloid cells' tumor-infiltrating properties to deliver interleukin-12 locally.

CYSTIC FIBROSIS AND LIFESPAN EXTENSION

  • Trial NCT07930884 is studying whether continuous glucose monitoring (CGM) can replace the 2-hour oral glucose tolerance test for detecting cystic fibrosis-related diabetes, noting that CFTR modulator therapies are extending CF patient lifespans and making long-term complication screening increasingly critical.

RARE DISEASE — VON WILLEBRAND AND EPILEPSY

  • Trial NCT06998524 is a Phase III multicenter open-label study of emicizumab prophylaxis in participants aged 1 month and above with Type 3 von Willebrand disease, the most severe subtype.
  • Trial NCT07723963 is evaluating JZP926 capsule for the treatment of juvenile myoclonic epilepsy, assessing both safety and efficacy.

MENOPAUSE AND HORMONAL AGING

  • Trial NCT07762287 is comparing bioavailability of two formulations of elinzanetant, a neurokinin-3 receptor antagonist used to manage menopausal hot flushes, in healthy women — relevant to hormone-free aging therapies.

📢 PUBLIC HEALTH

DRUG-RESISTANT BACTERIA ON THE RISE

  • A CDC report released Sept 23, 2025, documented a dramatic increase in dangerous drug-resistant bacteria across U.S. healthcare settings, underscoring the ongoing antimicrobial resistance threat.

CONGENITAL SYPHILIS — 12TH CONSECUTIVE ANNUAL INCREASE

  • CDC data published Sept 24, 2025, showed U.S. cases of syphilis in newborns increased for the 12th consecutive year in 2024, a persistent indicator of gaps in maternal prenatal screening.

RABIES ACTIVITY RISING

  • CDC issued a statement Sept 10, 2026, on increases in animal rabies activity and associated human exposures, urging veterinary and public health vigilance.

LUNG CANCER MORTALITY DECLINING

  • The annual Report to the Nation (CDC, Sept 22, 2026) found progress against lung cancer is driving down overall U.S. cancer mortality rates.

NOTE: This edition is for informational purposes only and does not constitute medical advice. Always consult a qualified health professional for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  4. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  5. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  6. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  7. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  8. Shamonda virus in human - France — WHO Disease Outbreak News
  9. Yellow fever - WHO African Region — WHO Disease Outbreak News
  10. Yellow fever - Global — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20261113-02-v135 · 2026-11-13 02:01 UTC · pulse.uzylab.com